Health Catalyst (HCAT) Aperçu de l'action
Health Catalyst, Inc. fournit des technologies et des services de données et d'analyse aux organismes de soins de santé aux États-Unis. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 2/6 |
| Croissance future | 0/6 |
| Performances passées | 0/6 |
| Santé financière | 4/6 |
| Dividendes | 0/6 |
HCAT Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Health Catalyst, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$2.25 |
| Plus haut sur 52 semaines | US$4.12 |
| Plus bas sur 52 semaines | US$0.96 |
| Bêta | 1.57 |
| Variation sur 1 mois | 27.12% |
| Variation sur 3 mois | 70.45% |
| Variation sur 1 an | -38.36% |
| Variation sur 3 ans | -82.49% |
| Variation sur 5 ans | -96.07% |
| Évolution depuis l'introduction en bourse | -94.26% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Jul 07
HCAT: Vitalware Sale And Impairment Charges Will Pressure Shares Further
Health Catalyst's analyst price target has shifted to $1.75 from $1, as analysts factor in the pending Vitalware sale and update their assumptions on fair value, discount rate, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on Health Catalyst highlights a mixed picture, with the updated US$1.75 price target reflecting both the pending Vitalware sale and an effort to recalibrate assumptions for fair value, discount rates, revenue growth, margins, and future P/E multiples.
Mise à jour du récit • Jun 23
HCAT: Cost Restructuring And Governance Changes Will Shape A Measured Turnaround
Analysts have trimmed their 12 month price target on Health Catalyst by $0.25, citing updated assumptions around fair value, growth expectations, profitability and future P/E multiples. What’s in the News for Health Catalyst Health Catalyst has scheduled its 2026 Annual Meeting of Stockholders for July 16, 2026, to be held via a live interactive audio webcast.
Mise à jour du récit • Jun 05
HCAT: Execution On Product Transition And Cost Cuts Will Shape 2026 Reset
Analysts have trimmed Health Catalyst's implied fair value to $2.00 per share from $5.00. This reflects a higher discount rate, a cut to longer term revenue expectations after softer Q1 guidance and a delayed FY26 outlook, and lower assumed future P/E multiples despite relatively stable profit margin assumptions.Recent updates
Mise à jour du récit • Jul 07
HCAT: Vitalware Sale And Impairment Charges Will Pressure Shares Further
Health Catalyst's analyst price target has shifted to $1.75 from $1, as analysts factor in the pending Vitalware sale and update their assumptions on fair value, discount rate, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on Health Catalyst highlights a mixed picture, with the updated US$1.75 price target reflecting both the pending Vitalware sale and an effort to recalibrate assumptions for fair value, discount rates, revenue growth, margins, and future P/E multiples.Mise à jour du récit • Jun 23
HCAT: Cost Restructuring And Governance Changes Will Shape A Measured Turnaround
Analysts have trimmed their 12 month price target on Health Catalyst by $0.25, citing updated assumptions around fair value, growth expectations, profitability and future P/E multiples. What’s in the News for Health Catalyst Health Catalyst has scheduled its 2026 Annual Meeting of Stockholders for July 16, 2026, to be held via a live interactive audio webcast.Mise à jour du récit • Jun 05
HCAT: Execution On Product Transition And Cost Cuts Will Shape 2026 Reset
Analysts have trimmed Health Catalyst's implied fair value to $2.00 per share from $5.00. This reflects a higher discount rate, a cut to longer term revenue expectations after softer Q1 guidance and a delayed FY26 outlook, and lower assumed future P/E multiples despite relatively stable profit margin assumptions.Mise à jour du récit • May 09
HCAT: New Leadership And AI Investments Will Drive Post Review Turnaround
Narrative Update on Health Catalyst The updated analyst price target for Health Catalyst has shifted lower toward a cluster around $2, reflecting analyst caution after reduced targets and commentary around softer near term guidance, the ongoing transition from DOS to Ignite, and the company’s current strategic and operational reviews. Analyst Commentary Recent research reflects a cautious stance on Health Catalyst, with price targets clustered in the US$1.75 to US$3.00 range and several firms highlighting execution risk around guidance, product transition, and ongoing reviews.Mise à jour du récit • Apr 24
HCAT: Guidance Reset And Impairment Charges Will Pressure Shares Further
Analyst price targets on Health Catalyst have been reset lower to a range of roughly $1.75 to $3, reflecting concerns about Q1 guidance, delayed FY26 outlook, product transition risks, and the need for more proof that the new leadership and AI-focused investments can gain traction. Analyst Commentary Recent Street research on Health Catalyst reflects a cautious reset in expectations, with multiple bearish analysts trimming price targets into a tighter US$1.75 to US$3 band and emphasizing execution and growth risks.Mise à jour du récit • Apr 08
HCAT: Earnings Uncertainty And Platform Transition Will Drive Further Downside Risk
Narrative Update on Health Catalyst The updated analyst price target for Health Catalyst has shifted sharply lower, with several firms cutting targets into a $1.75 to $3 range. Analysts are factoring in higher perceived risk, softer revenue and margin assumptions, and the earnings impact of the DOS to Ignite transition and the ongoing strategic review.Mise à jour du récit • Mar 25
HCAT: New Leadership And AI Investments Will Set Up 2026 Rebound
Analysts have reduced the base case price target on Health Catalyst from $3.88 to $2.09. The revision reflects a series of lower Street targets tied to softer near term growth assumptions, a higher discount rate, and calls for more clarity around the company’s product transition and ongoing reviews.Mise à jour du récit • Mar 11
HCAT: Lowered Sector Outlook Will Set Up Cautiously Optimistic 2026 Rebound
Analysts have trimmed their price target on Health Catalyst by $0.50 to $2.75. This reflects a more cautious view on near term sector challenges, while they maintain a neutral stance on the shares.Mise à jour du récit • Feb 24
HCAT: Cautiously Higher Future P/E And Reset Expectations Support Upside Potential
Analysts have trimmed their price target on Health Catalyst to $2.75 from $3.25, reflecting more cautious assumptions around revenue growth and risk, while remaining generally constructive on the sector heading into 2026. Analyst Commentary Bullish Takeaways Bullish analysts point to the lower US$2.75 target as still implying some value in Health Catalyst's data and analytics platform relative to current trading levels, even after a tough 2025 for the group.Article d’analyse • Feb 13
Improved Revenues Required Before Health Catalyst, Inc. (NASDAQ:HCAT) Shares Find Their Feet
With a price-to-sales (or "P/S") ratio of 0.4x Health Catalyst, Inc. ( NASDAQ:HCAT ) may be sending bullish signals at...Mise à jour du récit • Feb 10
HCAT: Lower 2025 Expectations Will Set Up Cautiously Optimistic 2026 Rebound
Analysts have trimmed their price expectations for Health Catalyst, with the latest target moving from US$3.25 to US$2.75 as they factor in what they describe as a challenging 2025 for health tech and a cautious outlook into 2026. Analyst Commentary Even with the lower target, bullish analysts see reasons to stay engaged with Health Catalyst, especially as the sector works through what they describe as a tough patch in 2025 and looks ahead to 2026.Mise à jour du récit • Jan 27
HCAT: Cautiously Higher Future P/E And Stable Margins Support Upside Potential
Analysts have trimmed their 12 month price target on Health Catalyst by $0.50 to $2.75, citing tougher assumptions around growth and margins, balanced by a slightly higher future P/E multiple and an updated risk outlook. Analyst Commentary Bullish Takeaways Bullish analysts point out that the revised US$2.75 target still reflects some confidence that the current valuation already prices in a tough recent period for health tech.Mise à jour du récit • Jan 10
HCAT: Cautious Sector Reset Will Still Support Future Revenue Visibility
Analysts have reduced their price target on Health Catalyst to $2.75 from $3.25, reflecting more cautious assumptions on revenue growth and margins, while maintaining a neutral stance on the stock. Analyst Commentary Bullish analysts are framing the lower US$2.75 price target as a recalibration rather than a shift in overall stance, with the neutral rating indicating that they see the current share price as broadly in line with their updated expectations.Mise à jour du récit • Dec 26
HCAT: Rising Discount Rate Will Still Support Strong Future Revenue Visibility
Analysts have reduced their price target on Health Catalyst by approximately $1.00 per share. This change reflects updated assumptions for a higher discount rate, slower revenue growth, and more muted profit margin and valuation expectations.Mise à jour du récit • Dec 11
HCAT: Stable Margins And Revenue Outlook Will Support Future Upside Potential
Narrative Update on Health Catalyst Analyst Price Target Analysts have modestly raised their price target on Health Catalyst by approximately 4 percent to around 3.94 dollars. This reflects slight adjustments to the discount rate and future earnings expectations, while views on revenue growth and profit margins remain largely unchanged.Mise à jour du récit • Nov 27
HCAT: Customer Partnerships Will Support Performance Despite Revised 2025 Revenue Outlook
Analysts have modestly lowered their price target for Health Catalyst. This adjustment is due to a slightly reduced profit margin outlook and a more conservative future price-to-earnings ratio, reflecting updated expectations for the company’s financial performance.Mise à jour du récit • Nov 13
HCAT: Ongoing Customer Relationships Will Drive Performance Amid Lower Revenue Guidance
Analysts have lowered their price target for Health Catalyst from $8 to $4. They cite recent reductions in revenue guidance, as well as expectations for lower growth and profitability.Article d’analyse • Oct 28
Improved Revenues Required Before Health Catalyst, Inc. (NASDAQ:HCAT) Shares Find Their Feet
You may think that with a price-to-sales (or "P/S") ratio of 0.8x Health Catalyst, Inc. ( NASDAQ:HCAT ) is definitely a...Mise à jour du récit • Aug 30
Modular AI Solutions Will Transform Value-Based Healthcare
Health Catalyst's price target has been cut as analysts cite persistent operating headwinds, declining revenue outlook, customer churn, market structural challenges, and heightened uncertainty from a CEO transition, resulting in a downward revision of fair value from $5.33 to $4.56. Analyst Commentary Weak first-half 2025 bookings and a reduction in revenue guidance, implicating lower net revenue retention and increased customer churn.Article d’analyse • Aug 13
Health Catalyst, Inc. (NASDAQ:HCAT) Just Reported Earnings, And Analysts Cut Their Target Price
NasdaqGS:HCAT 1 Year Share Price vs Fair Value Explore Health Catalyst's Fair Values from the Community and select...Mise à jour du récit • Aug 10
Modular AI Solutions Will Transform Value-Based Healthcare
Health Catalyst’s consensus price target has been reduced to $5.78, primarily reflecting a deterioration in net profit margin despite a lower discount rate. What's in the News CEO Dan Burton will step down effective June 2026, transitioning from his full-time role while continuing to assist the Board and serve as a director.Article d’analyse • Aug 04
Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Jun 10
Health Catalyst: Ignite Platform Is A Growth Catalyst
Summary I rate Health Catalyst a buy, driven by strong turnaround momentum and the transformative Ignite platform fueling faster growth and higher margins. Ignite's modular, lower-cost structure accelerates sales cycles, improves gross margins, and opens significant upsell opportunities within HCAT’s large existing customer base. Recent financials show accelerating revenue growth and strong client additions, supporting management’s FY25 guidance and signaling a potential inflection point for the business. Read the full article on Seeking AlphaArticle d’analyse • May 09
Health Catalyst, Inc. (NASDAQ:HCAT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
It's been a good week for Health Catalyst, Inc. ( NASDAQ:HCAT ) shareholders, because the company has just released its...
Nouveau récit • Mar 30
Ignite Transition And Recent Acquisitions Will Expand Global Footprint
Cross-selling through the Ignite platform is projected to boost client additions and accelerate revenue growth.Seeking Alpha • Mar 25
Health Catalyst: Share Price Continues To Dismiss Positive Earnings And Improved Outlook
Summary Despite a 50% drop in HCAT's stock price, the company shows significant growth, reporting $307M in revenue and $26M in adjusted EBITDA for 2024. Health Catalyst focuses on efficiency, exiting lower-margin segments, and pushing AI-driven efficiencies, aiming for improved margins and profitability in 2025. The company forecasts strong growth with 40 new platform clients in 2025 and expects $335M in revenue, trading at a significant discount compared to industry peers. Risks include potential revenue stall, macroeconomic challenges, and stock price volatility, but I remain cautiously optimistic, looking for a breakout to add to my position. Read the full article on Seeking AlphaArticle d’analyse • Mar 08
Take Care Before Jumping Onto Health Catalyst, Inc. (NASDAQ:HCAT) Even Though It's 27% Cheaper
To the annoyance of some shareholders, Health Catalyst, Inc. ( NASDAQ:HCAT ) shares are down a considerable 27% in the...Article d’analyse • Feb 27
Health Catalyst (NASDAQ:HCAT) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Rendement pour les actionnaires
| HCAT | US Healthcare Services | US Marché | |
|---|---|---|---|
| 7D | -1.7% | 1.4% | -2.0% |
| 1Y | -38.4% | -35.8% | 17.2% |
Rendement vs Industrie: HCAT a sous-performé le secteur US Healthcare Services qui a rapporté -35.8 % au cours de l'année écoulée.
Rendement vs marché: HCAT a sous-performé le marché US qui a rapporté 17.2 % au cours de l'année écoulée.
Volatilité des prix
| HCAT volatility | |
|---|---|
| HCAT Average Weekly Movement | 17.1% |
| Healthcare Services Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: Le cours de l'action de HCAT a été volatil au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de HCAT ( 17% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2008 | 1,200 | Ben Albert | www.healthcatalyst.com |
Health Catalyst, Inc. fournit des technologies et des services de données et d'analyse aux organismes de soins de santé aux États-Unis. L'entreprise opère dans deux secteurs : Technologie et Services professionnels. Elle propose la plateforme de données et d'analyse ignite qui fournit aux clients un environnement unique et complet pour intégrer et organiser les données de leurs systèmes logiciels disparates ; et les applications, un logiciel d'applications analytiques conçu pour la plateforme ignite afin d'analyser le visage des clients à travers l'amélioration clinique, l'amélioration des revenus et des coûts, les opérations ambulatoires, les mesures et les registres, ainsi que les données et l'analyse.
Health Catalyst, Inc. Résumé des fondamentaux
| HCAT statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$168.48m |
| Bénéfices(TTM) | -US$265.26m |
| Recettes(TTM) | US$302.48m |
0.5x
Ratio P/S-0.6x
Ratio P/ELe site HCAT est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| HCAT compte de résultat (TTM) | |
|---|---|
| Recettes | US$302.48m |
| Coût des recettes | US$149.90m |
| Marge brute | US$152.58m |
| Autres dépenses | US$417.83m |
| Les revenus | -US$265.26m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -3.59 |
| Marge brute | 50.44% |
| Marge bénéficiaire nette | -87.69% |
| Ratio dettes/capitaux propres | 111.0% |
Quelles ont été les performances à long terme de HCAT?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/17 15:49 |
| Cours de l'action en fin de journée | 2026/07/17 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Health Catalyst, Inc. est couverte par 16 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Zhilin Long | Berenberg |
| David Larsen | BTIG |
| Richard Close | Canaccord Genuity |